“The average branded drug loses roughly 80% of its revenue within 12 months of generic entry. What happens in the […]

Russia’s Drug Machine: Inside the Industry That Rewired Itself Overnight In 2024, the total value of the market reached 2.85

How patent cliffs, dual disease burdens, and a rising global middle class are redrawing the map of pharmaceutical competition —

The median pharmaceutical patent case where more than $25 million is at risk costs $4 million to litigate through trial

A technical deep dive for professionals who need more than a checklist. This is the architecture of a market-winning generic

For pharma IP teams, portfolio managers, R&D leads, and institutional investors tracking the $72B biosimilar market. 1. Executive Summary and

The U.S. healthcare system has already saved an estimated $23.6 billion from biosimilar use [1]. Yet for all that money

Generic drug development sits at the intersection of two disciplines that most organizations still treat as separate workstreams: intellectual property

A $2.23 billion bet on a molecule. A 90% chance it never reaches a patient. A 20-year patent clock that